0
0
NASHIK, India – In a significant advancement in oncology diagnostics, Indian researchers have developed a novel blood test capable of detecting up to 30 different types of cancer in their early stages with high accuracy. This groundbreaking test utilizes serum metabolomics combined with artificial intelligence (AI), offering a non-invasive and potentially cost-effective method for cancer screening.
The research, spearheaded by Dr. Nagarkar from a Nashik-based oncology centre, represents a potential paradigm shift, especially for cancer detection in resource-limited settings. The study involved a substantial cohort of 6,445 participants, which included 2,831 individuals diagnosed with various cancers who had not yet begun treatment, alongside healthy controls.
Unlike many existing liquid biopsy methods that primarily search for fragments of tumor DNA circulating in the blood, this innovative test focuses on metabolomics. It analyzes the profile of over 8,000 metabolites – small molecules involved in the body’s chemical processes – present in a serum sample. The underlying principle is that the development of cancer, even in its earliest stages, causes subtle but detectable systemic shifts in the body’s metabolism.
By employing sophisticated techniques like mass spectrometry to measure these metabolites and machine learning algorithms to identify patterns indicative of cancer, the test was able to achieve consistent accuracy across different age groups and genders in the study cohort.
Experts believe this metabolomics-based approach could be particularly sensitive for early-stage detection when tumor-specific markers might be scarce. The non-invasive nature of a simple blood draw, coupled with its potential for cost-effectiveness compared to more complex diagnostic procedures, makes it a promising tool for widespread screening programs.
While the initial results are highly encouraging, larger clinical trials are currently underway to further validate the test’s efficacy and reliability across diverse populations. If successful, this Indian-developed blood test could revolutionize cancer screening, leading to earlier diagnoses, more timely interventions, and ultimately, improved patient outcomes globally, particularly in regions with limited access to advanced medical technology.
Disclaimer: This news article is based on information sourced from Drug Today Online regarding a recent development in cancer diagnostics. The test is still undergoing further research and clinical validation. This information is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals for any health concerns or before making any decisions related to your health or treatment.1
